About Replimune
Replimune is a publicly listed company based in Oxford (United Kingdom) founded in 2015 by Philip Astley-Sparke. It operates as a developer of oncolytic immunotherapies. Replimune has raised $87 million across 3 funding rounds from investors including Atlas Venture, SVB Securities and Foresite Capital. The company has 479 employees. Its chief executive is Philip Astley-Sparke. Its website replimune.com draws about 15 thousand monthly visits. Replimune offers products and services including Oncolytic Immunotherapies and Investigational Therapies. Its focus areas include Life Sciences, Immunotherapy, Oncolytic Virus and Oncology. Its legal entity is REPLIMUNE LIMITED. Its competitors include Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Replimune was founded in 2015 in Oxford, United Kingdom, as a biotechnology company focused on oncolytic immunotherapies. A pipeline is being developed to strengthen direct anti-tumor effects via selective virus replication and to amplify immune reactions against released tumor antigens. Programs are advanced through clinical trials, with early integration of checkpoint blockade planned. Operations center on oncology, aiming for rapid progression in therapeutic development.
- Headquarters Oxford, United Kingdom
- Employees 479
- Founders Philip Astley-Sparke
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website replimune.com
- Social LinkedIn X
- Legal Name Replimune Group, Inc.
- Net Profit-$313.94 M (USD)-26.95as on Mar 31, 2026
- EBITDA-$314.99 M (USD)-21.2as on Mar 31, 2026
- Total Equity Funding$87M (USD)
in 3 rounds
- Latest Funding Round$55M (USD), Series B
Sep 2017
- InvestorsAtlas Venture
& 7 more
- Employee Count479
Products & Services of Replimune
Replimune offers a comprehensive portfolio of products and services, including Oncolytic Immunotherapies and Investigational Therapies.
Therapies designed to kill tumors and enhance immune responses against cancer.
Agents for treating solid tumor cancers in trials as single or combined options.
Funding Insights of Replimune
Replimune has successfully raised a total of $87M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $55 million completed in September 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $87M
- Total Rounds 3
- Last Round Series B — $55M
- First Round $2M
(Apr 2015)
- Investors Count 8
All 3 funding rounds of Replimune with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2017 | $55M | Series B | – | Foresite Capital | |
| Sep 2015 | $30M | Series A | – | – | |
| Apr 2015 | $2M | Seed | – | – | – |
8 investors in total: 8 institutional.
Investors in Replimune
Replimune has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Atlas Venture, SVB Securities and Foresite Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multi-stage investment firm invests in healthcare and life sciences companies | – | foresitecapital.com | New York, United States | |
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Venture capital firm focused on lifescience and healthcare sectors | – | forbion.com | Naarden, Netherlands | |
Investments are focused on pharmaceutical, biotechnology, and medical sectors. | – | baincapitallifesciences.com | Boston, United States | |
Venture capital firm | – | omegafunds.com | Boston, United States | |
Operates as an employee-owned hedge fund focused on long/short equity strategies. | 2007 | redmilegroup.com | San Francisco, United States | |
Investment in biopharma is facilitated by Omega Funds. | – | omegafunds.net | Boston, United States | |
M&A advisory services are provided for healthcare companies. | 1995 | svbsecurities.com | Boston, United States |
Investor details for Replimune
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Replimune
9 people are tracked at Replimune (8 in leadership, 1 in team); the tracked headcount is 479.
| Name | Role | Group |
|---|---|---|
Philip Astley-Sparke | Co-Founder, CEO & Executive Chairman | Leadership |
Robert Coffin | Founder, President and Chief Research & Development Officer | Leadership |
Tanya Lewis | Chief Development Operations Officer | Leadership |
Chris Sarchi | Chief Commercial Officer | Leadership |
Colin Love | Chief Operating Officer | Leadership |
Kostas Xynos | Chief Medical Officer | Leadership |
Emily Hill | Chief Operating Officer | Leadership |
Pamela Esposito | Chief Business Officer | Leadership |
Sushil Patel | CCO | Team |
Complete people profiles for Replimune
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Replimune
Replimune is a publicly listed company on the NASDAQ with ticker symbol REPL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date20 Jun 2018
- Listed onNASDAQ: REPL
- Listed entityReplimune Group, Inc.
- Exchange sectorHealth technology
- ISINUS76029N1063
- Share price$12.11 (-7.35% on the day) · 2026-10-13
- Market capitalisation$1.14B
- EPS (diluted, trailing year)$-3.28
- Volume (last session)1,632,148
Financials of Replimune
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -$313.9M | -$315.0M |
| 2024 | – | -$247.3M | -$259.9M |
| 2023 | – | -$215.8M | -$234.0M |
| 2022 | – | -$174.3M | -$177.6M |
| 2021 | – | -$118.0M | -$116.9M |
Detailed financial statements for Replimune
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Replimune
4 dated milestones of Replimune across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Replimune is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Series B, of $55.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Replimune
Replimune has 9 listed competitors in our database, 8 of them funded. They include Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of Replimune
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Replimune
The website of Replimune (replimune.com) receives about 15K visits a month and ranks #2,770,489 among all websites worldwide, #3,730 in Biotechnology and Pharmaceuticals.
- Monthly visits15K
▲ 80.6% vs previous month
- Unique visitors3.6K
per month
- Global rank#2,770,489
among all websites
- Category rank#3,730
Health · Biotechnology and Pharmaceuticals
- Bounce rate54%
- Pages per visit1.4
- Average visit4 sec
- DevicesDesktop 29% · Mobile 71%
Websites whose visitors overlap most with Replimune. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| oncologypipeline.com | 100% | 76.4K | #510,302 | View details | |
pharmexec.com | pharmexec.com | 97% | – | #565,102 | – |
aimatmelanoma.org | aimatmelanoma.org | 69% | – | – | – |
targetedonc.com | targetedonc.com | 58% | – | #379,902 | – |
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as Replimune (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Replimune
Complete news archive for Replimune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Replimune
Replimune was founded in 2015.
Replimune is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Philip Astley-Sparke is the current CEO of Replimune. They have also founded this company.
Replimune is a funded company, having raised a total of $87M across 3 funding rounds to date. The company's 1st funding round was a Seed of $2M, raised on Apr 2015.
Replimune has 479 employees.
Replimune was founded in 2015 in Oxford, United Kingdom, as a biotechnology company focused on oncolytic immunotherapies. A pipeline is being developed to strengthen direct anti-tumor effects via selective virus replication and to amplify immune reactions against released tumor antigens. Programs are advanced through clinical trials, with early integration of checkpoint blockade planned. Operations center on oncology, aiming for rapid progression in therapeutic development.
Replimune's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Replimune offers Oncolytic Immunotherapies and Investigational Therapies.
Yes, Replimune is publicly traded on NASDAQ under the ticker symbol REPL.
Replimune has 8 investors. Key investors include Atlas Venture, SVB Securities, Foresite Capital, Redmile Group, and Forbion.
Replimune operates through Replimune Limited.